Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age19+
SponsorSamsung Medical Center
About this trial
The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery.
The main questions it aims to answer are:
* 7-year ipsilateral breast tumor recurrence * 7-year disease-free survival * 7-year locoregional recurrence * 7-year overall survival * Adverse events of radiation therapy
Participants will be assessed by multi-dimensional methods after radiation therapy:
* Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * Assessment for the adverse events according to CTCAE version 5.0
Eligibility criteria
Qualifiers
Female patients with age minimum 19
Pathological confirmation of HER2+ invasive breast cancer
Eastern Cooperative Oncology Group performance status 0-2
Informed consent of the participant
Disqualifiers
Pathological confirmation of ductal carcinoma in situ of the breast
Previous history of radiation therapy to ipsilateral breast
Trial design
Treatments tested in this trial
- Whole breast irradiation +/- tumor bed boost
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov